SLC5A2 and kidney disorder: Multiple large trials have demonstrated the kidney protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with kidney diseases beyond diabetic nephropathy, thought to be mediated primarily through natriuresis, reduction in intraglomerular pressure, blood pressure reduction, and/or weight loss.